{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:32:37Z","timestamp":1794256357857,"version":"4.9.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Municipal Health Commission's Excellence in Clinical Research Program for Research Wards","award":["BRWEP2024W072130113"],"award-info":[{"award-number":["BRWEP2024W072130113"]}]},{"name":"Beijing Municipal Health Commission's Excellence in Clinical Research Program for Research Wards","award":["BRWEP2024W072130113"],"award-info":[{"award-number":["BRWEP2024W072130113"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-025-07033-6","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T09:41:09Z","timestamp":1749202869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Identifying factors related to sertraline concentrations in child\/adolescent and adult patients: insights from a therapeutic drug monitoring service"],"prefix":"10.1186","volume":"25","author":[{"given":"Ruoming","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Hasenqimuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"7033_CR1","unstructured":"Collaborators GDI. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Volume 396. Lancet; 2020. pp. 1204\u201322. 10258."},{"issue":"10440","key":"7033_CR2","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","volume":"403","author":"GF Collaborators","year":"2024","unstructured":"Collaborators GF. Burden of disease scenarios for 204 countries and territories, 2022\u20132050: a forecasting analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2204\u201356.","journal-title":"Lancet"},{"issue":"12","key":"7033_CR3","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S2215-0366(21)00292-3","volume":"8","author":"R Brauer","year":"2021","unstructured":"Brauer R, et al. Psychotropic medicine consumption in 65 countries and regions, 2008-19: a longitudinal study. Lancet Psychiatry. 2021;8(12):1071\u201382.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"7033_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/FPC.0000000000000392","volume":"30","author":"R Huddart","year":"2020","unstructured":"Huddart R, et al. PharmGKB summary: Sertraline pathway, pharmacokinetics. Pharmacogenet Genomics. 2020;30(2):26\u201333.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"7033_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/wps.20765","volume":"19","author":"M Solmi","year":"2020","unstructured":"Solmi M, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020;19(2):214\u201332.","journal-title":"World Psychiatry"},{"issue":"6","key":"7033_CR6","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1037\/amp0000904","volume":"77","author":"Guideline-Development-Panel-for-the","year":"2022","unstructured":"Guideline-Development-Panel-for-the-Treatment-of-Depressive-Disorders. Summary of the clinical practice guideline for the treatment of depression across three age cohorts. Am Psychol. 2022;77(6):770\u201380.","journal-title":"Am Psychol"},{"key":"7033_CR7","doi-asserted-by":"publisher","first-page":"115391","DOI":"10.1016\/j.psychres.2023.115391","volume":"327","author":"X Luo","year":"2023","unstructured":"Luo X, et al. Selection of the optimal dose of Sertraline for depression: A dose-response meta-analysis of randomized controlled trials. Psychiatry Res. 2023;327:115391.","journal-title":"Psychiatry Res"},{"key":"7033_CR8","doi-asserted-by":"crossref","unstructured":"Schoretsanitis G et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American society of clinical psychopharmacology and the therapeutic drug monitoring task force of the arbeitsgemeinschaft f\u00fcr neuropsychopharmakologie und pharmakopsychiatrie. J Clin Psychiatry. 2020;81(3):19cs13169.","DOI":"10.4088\/JCP.19cs13169"},{"key":"7033_CR9","doi-asserted-by":"crossref","unstructured":"Pennazio F, et al. Current status of therapeutic drug monitoring in mental health treatment: A review. Volume 14. Pharmaceutics; 2022. 12.","DOI":"10.3390\/pharmaceutics14122674"},{"issue":"5","key":"7033_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/hup.599","volume":"19","author":"M Reis","year":"2004","unstructured":"Reis M, et al. Serum disposition of Sertraline, N-desmethylsertraline and Paroxetine: a Pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol. 2004;19(5):283\u201391.","journal-title":"Hum Psychopharmacol"},{"issue":"3","key":"7033_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/clpt.2013.221","volume":"95","author":"S Crettol","year":"2014","unstructured":"Crettol S, et al. Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. Clin Pharmacol Ther. 2014;95(3):254\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"1\u201302","key":"7033_CR12","first-page":"9","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1\u201302):9\u201362.","journal-title":"Pharmacopsychiatry"},{"key":"7033_CR13","doi-asserted-by":"publisher","first-page":"152301","DOI":"10.1016\/j.comppsych.2022.152301","volume":"115","author":"E Tini","year":"2022","unstructured":"Tini E, et al. Therapeutic drug monitoring of Sertraline in children and adolescents: A naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder. Compr Psychiatry. 2022;115:152301.","journal-title":"Compr Psychiatry"},{"key":"7033_CR14","doi-asserted-by":"publisher","first-page":"1289673","DOI":"10.3389\/fphar.2024.1289673","volume":"15","author":"R Fu","year":"2024","unstructured":"Fu R, et al. Machine learning-based prediction of Sertraline concentration in patients with depression through therapeutic drug monitoring. Front Pharmacol. 2024;15:1289673.","journal-title":"Front Pharmacol"},{"key":"7033_CR15","doi-asserted-by":"crossref","unstructured":"Zhang Z, et al. Population Pharmacokinetic approach to guide personalized Sertraline treatment in Chinese patients. Heliyon. 2024;10(3):e25231.","DOI":"10.1016\/j.heliyon.2024.e25231"},{"issue":"3","key":"7033_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00228-023-03611-3","volume":"80","author":"K Tveit","year":"2024","unstructured":"Tveit K, et al. Age of onset for increased dose-adjusted serum concentrations of antidepressants and association with sex and genotype: an observational study of 34,777 individuals. Eur J Clin Pharmacol. 2024;80(3):435\u201344.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"7033_CR17","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40262-023-01294-8","volume":"62","author":"EA Poweleit","year":"2023","unstructured":"Poweleit EA, et al. Escitalopram and Sertraline population Pharmacokinetic analysis in pediatric patients. Clin Pharmacokinet. 2023;62(11):1621\u201337.","journal-title":"Clin Pharmacokinet"},{"key":"7033_CR18","doi-asserted-by":"crossref","unstructured":"Castillo CEC, et al. Population pharmacokinetics of Sertraline in psychiatric and substance use disorders. J Clin Pharmacol. 2024;64(10):1267\u201377.","DOI":"10.1002\/jcph.2457"},{"issue":"4","key":"7033_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/clpt.2008.302","volume":"85","author":"ET Morgan","year":"2009","unstructured":"Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"7033_CR20","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jaac.2020.08.006","volume":"60","author":"LB Ramsey","year":"2021","unstructured":"Ramsey LB, et al. Thoughtful clinical use of pharmacogenetics in child and adolescent psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2021;60(6):660\u20134.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"7033_CR21","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1111\/bcp.14821","volume":"88","author":"BD Chapron","year":"2022","unstructured":"Chapron BD, et al. Recent advances in the ontogeny of drug disposition. Br J Clin Pharmacol. 2022;88(10):4267\u201384.","journal-title":"Br J Clin Pharmacol"},{"key":"7033_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fphar.2019.00099","volume":"10","author":"SL Aldrich","year":"2019","unstructured":"Aldrich SL, et al. Influence of CYP2C19 metabolizer status on Escitalopram\/Citalopram tolerability and response in youth with anxiety and depressive disorders. Front Pharmacol. 2019;10:99.","journal-title":"Front Pharmacol"},{"key":"7033_CR23","doi-asserted-by":"crossref","unstructured":"Klomp SD, et al. Phenoconversion of cytochrome P450 metabolism: a systematic review. J Clin Med. 2020;9(9):2890.","DOI":"10.3390\/jcm9092890"},{"issue":"3","key":"7033_CR24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1124\/dmd.114.061093","volume":"43","author":"RR Shah","year":"2015","unstructured":"Shah RR, et al. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos. 2015;43(3):400\u201310.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"7033_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00702-018-1922-0","volume":"126","author":"S Mostafa","year":"2019","unstructured":"Mostafa S, et al. An analysis of allele, genotype and phenotype frequencies, actionable Pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes. J Neural Transm (Vienna). 2019;126(1):5\u201318.","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"7033_CR26","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/cpt.3534","volume":"117","author":"S Gerlach","year":"2025","unstructured":"Gerlach S, et al. Prevalence estimates of cytochrome P450 phenoconversion in youth receiving pharmacotherapy for mental health conditions. Clin Pharmacol Ther. 2025;117(3):670\u20135.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"7033_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/FTD.0b013e31827ada88","volume":"35","author":"J de Leon","year":"2013","unstructured":"de Leon J, et al. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit. 2013;35(1):30\u201347.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"7033_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cpt.2903","volume":"114","author":"CA Bousman","year":"2023","unstructured":"Bousman CA, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharmacol Ther. 2023;114(1):51\u201368.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"7033_CR29","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41431-021-01004-7","volume":"30","author":"J Brouwer","year":"2022","unstructured":"Brouwer J, et al. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. Eur J Hum Genet. 2022;30(10):1114\u201320.","journal-title":"Eur J Hum Genet"},{"issue":"10","key":"7033_CR30","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1681\/ASN.2006040368","volume":"17","author":"YC Ma","year":"2006","unstructured":"Ma YC, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937\u201344.","journal-title":"J Am Soc Nephrol"},{"key":"7033_CR31","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jpba.2017.07.009","volume":"145","author":"M Iguiniz","year":"2017","unstructured":"Iguiniz M, et al. Two-dimensional liquid chromatography in pharmaceutical analysis. Instrumental aspects, trends and applications. J Pharm Biomed Anal. 2017;145:482\u2013503.","journal-title":"J Pharm Biomed Anal"},{"key":"7033_CR32","unstructured":"ZOLOFT Package Insert. [https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/019839s108,20990s062lbl.pdf,ac]."},{"issue":"3","key":"7033_CR33","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41386-019-0554-x","volume":"45","author":"LS Br\u00e5ten","year":"2020","unstructured":"Br\u00e5ten LS, et al. Impact of CYP2C19 genotype on Sertraline exposure in 1200 Scandinavian patients. Neuropsychopharmacology. 2020;45(3):570\u20136.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"7033_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/FTD.0000000000000101","volume":"37","author":"C Gjestad","year":"2015","unstructured":"Gjestad C, et al. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors Citalopram, Escitalopram, and Sertraline. Ther Drug Monit. 2015;37(1):90\u20137.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"7033_CR35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/bcpt.12796","volume":"121","author":"MR Hansen","year":"2017","unstructured":"Hansen MR, et al. Therapeutic drug monitoring of Venlafaxine in an everyday clinical setting: analysis of age, sex and dose concentration relationships. Basic Clin Pharmacol Toxicol. 2017;121(4):298\u2013302.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"7033_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","volume":"31","author":"M Reis","year":"2009","unstructured":"Reis M, et al. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit. 2009;31(1):42\u201356.","journal-title":"Ther Drug Monit"},{"key":"7033_CR37","doi-asserted-by":"crossref","unstructured":"Romanescu M, et al. Sex-related differences in pharmacological response to CNS drugs: a narrative review. J Pers Med. 2022;12(6):907.","DOI":"10.3390\/jpm12060907"},{"issue":"3","key":"7033_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1017\/S1092852912001010","volume":"18","author":"D Marazziti","year":"2013","unstructured":"Marazziti D, et al. Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex. CNS Spectr. 2013;18(3):118\u201327.","journal-title":"CNS Spectr"},{"issue":"2","key":"7033_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cld.2012.03.006","volume":"16","author":"TH Lee","year":"2012","unstructured":"Lee TH, et al. Evaluation of elevated liver enzymes. Clin Liver Dis. 2012;16(2):183\u201398.","journal-title":"Clin Liver Dis"},{"issue":"Suppl 1","key":"7033_CR40","first-page":"S188","volume":"61 Suppl 1","author":"K Hoshitsuki","year":"2021","unstructured":"Hoshitsuki K, et al. Pharmacogenomics for drug dosing in children: current use, knowledge, and gaps. J Clin Pharmacol. 2021;61 Suppl 1(Suppl 1):S188\u201392.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"7033_CR41","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S0090-9556(24)15222-1","volume":"27","author":"K Kobayashi","year":"1999","unstructured":"Kobayashi K, et al. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos. 1999;27(7):763\u20136.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"7033_CR42","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1124\/dmd.104.002428","volume":"33","author":"RS Obach","year":"2005","unstructured":"Obach RS, et al. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005;33(2):262\u201370.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"7033_CR43","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00204-020-02753-y","volume":"94","author":"S Chen","year":"2020","unstructured":"Chen S, et al. The role of hepatic cytochrome P450s in the cytotoxicity of Sertraline. Arch Toxicol. 2020;94(7):2401\u201311.","journal-title":"Arch Toxicol"},{"key":"7033_CR44","doi-asserted-by":"publisher","first-page":"114354","DOI":"10.1016\/j.psychres.2021.114354","volume":"308","author":"SV Parikh","year":"2022","unstructured":"Parikh SV, et al. Combinatorial Pharmacogenomic algorithm is predictive of Sertraline metabolism in patients with major depressive disorder. Psychiatry Res. 2022;308:114354.","journal-title":"Psychiatry Res"},{"issue":"5","key":"7033_CR45","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/cpt.2695","volume":"112","author":"CS Pridgeon","year":"2022","unstructured":"Pridgeon CS, et al. Liquid biopsies or therapeutic drug monitoring for CYP activity profile determination. Clin Pharmacol Ther. 2022;112(5):1000\u20133.","journal-title":"Clin Pharmacol Ther"},{"key":"7033_CR46","doi-asserted-by":"crossref","unstructured":"Orsolini L, et al. C-reactive protein as a biomarker for major depressive disorder? Int J Mol Sci. 2022;23(3):1616.","DOI":"10.3390\/ijms23031616"},{"issue":"9","key":"7033_CR47","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00213-015-3976-0","volume":"233","author":"G Hefner","year":"2016","unstructured":"Hefner G, et al. Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. Psychopharmacology. 2016;233(9):1695\u2013705.","journal-title":"Psychopharmacology"},{"key":"7033_CR48","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jpsychires.2024.01.002","volume":"170","author":"S Pan","year":"2024","unstructured":"Pan S, et al. Relationship between C-reactive protein and antipsychotics levels in schizophrenic patients infected with COVID-19. J Psychiatr Res. 2024;170:297\u2013301.","journal-title":"J Psychiatr Res"},{"key":"7033_CR49","doi-asserted-by":"publisher","first-page":"107627","DOI":"10.1016\/j.pharmthera.2020.107627","volume":"215","author":"F Stanke-Labesque","year":"2020","unstructured":"Stanke-Labesque F, et al. Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol Ther. 2020;215:107627.","journal-title":"Pharmacol Ther"},{"key":"7033_CR50","doi-asserted-by":"crossref","unstructured":"Oliveira P, et al. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry. 2017;16:17.","DOI":"10.1186\/s12991-017-0140-8"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07033-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-07033-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07033-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T09:41:14Z","timestamp":1749202874000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-07033-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7033"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-07033-6","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study, conducted in accordance with the Declaration of Helsinki and with waived informed consent, was approved by the Ethics Committee of The Second People\u2019s Hospital of Guizhou Province in China [(2024) Research No. 03].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Given that this study was a retrospective study utilizing data from electronic medical records, the Ethics Committee granted a waiver of informed consent, as the study posed no additional risk to participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"590"}}